Clinical trials
Cholangitis clinical trials
Below are recruiting cholangitis clinical trials, each written for real people, not researchers. We’re tracking 63 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06755541RecruitingPhase 3
Fenofibrate plus ursodeoxycholic acid for PBC: a real-world study
This trial is testing whether adding fenofibrate to the standard PBC medicine ursodeoxycholic acid helps people with primary biliary cholangitis. It's a real-world study, meaning it looks at how treatments work in everyday practice. You can join only if you have already completed an earlier fenofibrate study.
Xi'an, ShaanxiAges 18–75 - NCT06767605Recruiting
Spanish registry for autoimmune liver diseases
This study collects information from people with autoimmune or cholestatic liver diseases to better understand them and improve care. It does not test a new treatment, but your participation can help future research.
BarcelonaAges 18 years+ - NCT06905054RecruitingPhase 2
Preventing PSC recurrence after liver transplant
This trial tests whether fenofibrate can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. It is for adults who had a liver transplant for PSC between 1 and 7 years ago and have certain risk factors.
Scottsdale, ArizonaAges 18–75 - NCT07161245Recruiting
Fatigue relief study for primary biliary cholangitis
This trial tests a program of exercise, nutrition, and education to help reduce fatigue in people with primary biliary cholangitis. It aims to see if this program can improve energy and quality of life.
Barcelona, BarcelonaAges 18–80 - NCT07205874Recruiting
Finding PBC early in people with positive AMA
This study looks for early signs of Primary Biliary Cholangitis in people who have a positive AMA blood test but normal liver enzyme levels. It aims to find the disease before it causes symptoms.
MadridAges 18–80 - NCT07229911RecruitingPhase 1
Study of TAK-781 in healthy people and PSC patients
This study tests an investigational drug called TAK-781 in healthy volunteers and in people with primary sclerosing cholangitis (PSC) who do not have cirrhosis. The study aims to see how the drug is processed by the body and whether it is safe.
Salt Lake City, UtahAges 18–68 - NCT06016842RecruitingPhase 3
Long-term study of elafibranor for primary biliary cholangitis
This trial tests a drug called elafibranor for people with primary biliary cholangitis (PBC), a liver disease. It aims to see if the drug is safe and works well over a long time.
Tucson, ArizonaAges 18 years+ - NCT07304843RecruitingPhase 1/Phase 2
Testing golexanolone for fatigue and brain fog in PBC
This study tests an experimental drug called golexanolone to see if it can help with fatigue and thinking problems in people with primary biliary cholangitis (PBC). It involves taking two different doses of the drug and checking how you feel and think over time.
DüsseldorfAges 18 years+ - NCT03146910Recruiting
Study of primary biliary cholangitis in Switzerland
This study follows adults with primary biliary cholangitis (a long-term liver and bile duct condition). It may help doctors better understand the disease in different people, including those identified by specific blood antibody tests.
Lugano, Canton TicinoAges 18 years+ - NCT02137668RecruitingPhase 1
Testing vancomycin for certain pediatric bile duct conditions
This early-phase study tests whether the antibiotic vancomycin can help children with primary sclerosing cholangitis or biliary atresia, and related gut/bile duct problems. It may work by changing gut bacteria, but you would need to avoid certain medicines beforehand.
Sacramento, CaliforniaAges 2 weeks–40 years - NCT07407491RecruitingPhase 2
Antibiotic during ERCP for bile duct infection
This trial tests if giving an antibiotic directly into the bile duct during an ERCP procedure helps treat acute cholangitis better than standard care. If you have mild or moderate cholangitis and are scheduled for ERCP within 48 hours, you may be a candidate.
Cheras, Kuala LumpurAges 18 years+ - NCT07449793Recruiting
PBC treatment response and long-term health outcomes
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT07607353Recruiting
Biodegradable Stents for Primary Sclerosing Cholangitis
This trial tests a new type of stent (a small tube placed in bile ducts) that dissolves on its own over time in patients with primary sclerosing cholangitis (PSC), a rare disease affecting the bile ducts. The goal is to widen narrowed ducts and reduce the need for repeated procedures.
LondonAges 18 years+ - NCT07631442Enrolling by invitation
Digital Health Monitoring for Primary Biliary Cholangitis
This study uses a smartphone app or digital platform to track how you're feeling day-to-day if you have primary biliary cholangitis (PBC), a liver condition where your immune system damages bile ducts. Researchers want to see if this digital monitoring helps them better understand and manage PBC symptoms.
Redwood City, CaliforniaAges 18 years+ - NCT06591468Enrolling by invitationPhase 2/Phase 3
Prednisone Plus Ursodeoxycholic Acid for PBC Patients
This trial tests adding prednisone (a steroid) to ursodeoxycholic acid (a bile acid medicine) for people with primary biliary cholangitis who have a specific type of liver inflammation. The goal is to see if the combination works better at controlling the disease than standard care.
Guangzhou, GuangdongAges 18–75 - NCT03175471Recruiting
MRI study of blood-vessel and tissue signs in child liver disease
This trial uses MRI scans to look for “biomarkers,” which are measurable signs in the liver, to better understand autoimmune liver diseases in children and teens. It may help doctors track disease and improve care by finding imaging patterns linked to illness.
Cincinnati, OhioAges 6–23 - NCT06865924Recruiting
Understanding genetic causes in atypical PSC using liver cells
This study creates mini-livers (colangioids) from tiny tissue samples to find genetic reasons for atypical primary sclerosing cholangitis (aPSC), a rare liver disease. It aims to help doctors better understand and diagnose the condition.
Milan, MIAges 18–90 - NCT06297993Recruiting
Global study following adults with PSC
This study follows adults with primary sclerosing cholangitis (PSC) over time to learn more about the condition. It is observational, meaning no new treatments are tested—just regular checkups and data collection to better understand PSC.
Sacramento, CaliforniaAges 18–75 - NCT05835505RecruitingPhase 2
Detox medicine study for primary sclerosing cholangitis
This Phase 2 trial studies a “detoxification” approach to improve liver and bile-duct function in people with primary sclerosing cholangitis (PSC). It may help lower abnormal bile flow markers and see whether the treatment is safe for your liver.
Chestnut Hill, MassachusettsAges 18–75 - NCT03445585Recruiting
Biobank study for primary sclerosing and primary biliary cholangitis
This study collects and stores samples from people with PSC (primary sclerosing cholangitis), PBC (primary biliary cholangitis), and some related liver conditions. Researchers use these samples to better understand these diseases and support future research.
Rochester, MinnesotaAges 18–85 - NCT04037007Recruiting
Fistulotomy during ERCP to open the bile duct entrance
This trial looks at whether a specific small procedure during ERCP helps doctors reach and drain the bile duct when gallstones or bile duct narrowing are suspected. It may help people avoid getting stuck during the procedure and improve how successfully the bile duct can be reached.
Mexico City, Mexico CityAges 18–90 - NCT04514965Recruiting
Bezafibrate for primary biliary cholangitis patients
This trial studies whether bezafibrate, a medication, can help people with primary biliary cholangitis (PBC). You may be considered if your care team is already considering bezafibrate and you meet safety requirements.
Aarhus N, Central JutlandAges 18–99 - NCT04650243RecruitingPhase 4
Testing whether lowering UDCA helps people with PBC
This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.
BeijingAges 18 years+ - NCT04753996Recruiting
Testing bile-based “mini-liver” samples in PSC and non-PSC groups
This study collects bile and uses it to grow small lab models (organoids) from people with primary sclerosing cholangitis (PSC) and from people without PSC. Researchers want to better understand how PSC changes bile cells, which could improve future diagnosis or treatments.
Rochester, MinnesotaAges 18–85
Hear when a new Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cholangitis?
- Yes. Clin2 currently lists 63 recruiting cholangitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cholangitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cholangitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.